1. Introduction {#s1}
===============

Cachexia is a complex metabolic syndrome of which chronic illnesses such as chronic obstructive pulmonary disease (COPD), chronic heart failure (HF), cancer, and chronic kidney disease (CKD) are the common leading causes, in order.[@b1],[@b2] Cachexia associated with chronic HF is known as cardiac cachexia (CC), with a prevalence ranging from 5% to 15% in patients with chronic HF.[@b2],[@b3] CC is related to hemodynamic alterations such as congestion[@b4],[@b5] and consequent proinflammation, malabsorption, anorexia, and neurohormonal activation.[@b5]--[@b8] The presence of CC is a predictor of adverse prognosis, including all-cause death.[@b3],[@b4],[@b9],[@b10]

On the other hand, patients with HF have various prognostic risk factors in addition to CC, including impaired renal function, aging, and anemia.[@b3],[@b10]--[@b12] However, since CC has a multifactorial underlying pathophysiology in nature,[@b1],[@b5],[@b13] we hypothesized that the presence of CC alters the prognostic impact of these general risk factors in patients with HF. Thus, in the current study, we aimed to elucidate: (1) the interactions between the respective impacts of CC and coexisting prognostic risk factors; and (2) the independent prognostic risk factors and their impact in patients with CC.

2. Methods {#s2}
==========

2.1. Study design and patient population {#s2a}
----------------------------------------

This was a prospective observational cohort study of 2213 patients who were hospitalized at Fukushima Medical University Hospital for decompensated HF between January 2010 and December 2017. Diagnosis of HF was made by each attending cardiologist on the basis of the current guidelines.[@b3],[@b10] The exclusion criteria (*n* = 605) were as follows: (1) patients who were receiving maintenance dialysis; and (2) patients whose medical records were incomplete regarding body mass index (BMI), C-reactive protein (CRP), hemoglobin, and/or albumin. Finally, 1608 patients were included in this study. CC was defined on the basis of the previous studies as the combination of BMI \< 20 kg/m^2^ and at least one of the following biochemical abnormalities: CRP \> 5 mg/L, hemoglobin \< 12 g/dL, and/or albumin \< 3.2 g/dL.[@b1],[@b4],[@b14] We divided these patients based on the presence (the CC group *n* = 176, 10.9%) or absence (the non-CC group *n* = 1432, 89.1%) of CC. We compared the patients\' characteristics and clarified post-discharge prognosis for cardiac event and all-cause death. A cardiac event was defined as rehospitalization due to worsening HF or cardiac death.[@b15] Cardiac death was defined as death due to worsening HF, acute coronary syndrome, or ventricular fibrillation documented by electrocardiogram or implantable devices.[@b15]

All subjects gave written informed consent to participate in the study. The study protocol was approved by the ethical committee of Fukushima Medical University. The investigation conforms with the principles outlined in the Declaration of Helsinki. Reporting of the study conforms with STROBE along with references to STROBE and the broader EQUATOR guidelines.

2.2. Data collection and classification {#s2b}
---------------------------------------

The patients\' characteristics included demographic data and medications at the time of discharge. Blood samples and echocardiographic data were obtained within one week prior to discharge. Estimated glomerular filtration rate (eGFR) was calculated using the modified Modification of Diet in Renal Disease equation: eGFR (mL/min per 1.73 m^2^) = 194 × serum creatinine ^(−1.094)^ × age ^(−0.287)^ × 0.739 (if female).[@b16] As post-discharge follow-ups, status and dates of endpoints were obtained from the patients\' medical records. If these data were unavailable, status was ascertained by a telephone call to the patient\'s referring hospital physician.[@b15]

Comorbidities were defined in accordance with the preceding studies.[@b15],[@b17],[@b18] Peripheral artery disease was diagnosed according to the guidelines using computed tomography, angiography, and/or ankle-brachial index.[@b17] Cancer was identified from the patient\'s medical records.[@b15] COPD was diagnosed based on the patient\'s medical records, the usage of drugs to treat COPD, or the results of spirometry (forced expiratory volume in 1 second/forced vital capacity \< 0.70).[@b19],[@b20]

2.3. Statistical analysis {#s2c}
-------------------------

Normality was confirmed using the Shapiro-Wilk test in each group. Normally distributed variables were presented as mean ± SD, non-normally distributed variables were presented as median (interquartile range), and categorical variables were expressed as counts and percentages. Normally distributed variables were compared using the Student\'s *t*-test, non-normally distributed variables were compared using the Mann-Whitney *U* test, and the chi-square test was used for comparisons of categorical variables. Kaplan-Meier analysis was used to assess the two primary endpoints (cardiac event and all-cause death), and a log-rank test was used for initial comparisons. To fit the multifactorial pathophysiology of CC, clinically important prognostic risk factors were evaluated by the univariable Cox proportional hazard analysis separately based on the presence or absence of CC. Then, each prognostic risk factor, CC, and interaction between each prognostic risk factor and CC, were entered into a multivariable Cox proportional hazard model to obtain interaction *P* values. Moreover, we performed univariable and multivariable Cox proportional hazard analyses in the CC group. Risk factors which had *P* values of \< 0.05 in univariable model were entered into multivariable model. The survival classification and regression tree (CART) analysis were then performed in the CC group to determine the optimal cut-off points in predicting the endpoints if factors had *P* values of \< 0.05 in the multivariable model. These cut-off points were verified by the Kaplan-Meier analysis. *P* values of \< 0.05 were considered statistically significant for all analyses. The survival CART analysis were performed with EZR ver. 1.40 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R ver. 3.5.2 (The R Foundation for Statistical Computing, Vienna, Austria). All other analyses were performed using SPSS ver. 26 (IBM, Armonk, NY, USA).

3. Results {#s3}
==========

3.1. Baseline patient characteristics {#s3a}
-------------------------------------

In the current study, 176 of 1608 patients (10.9%) belonged to the CC group. The comparisons of patients\' characteristics are summarized in [Table 1](#jgc-17-01-026-t01){ref-type="table"}. The CC group patients were older, had a lower prevalence of male sex, lower BMI, and lower systolic blood pressure, compared with the non-CC group patients. With respect to past medical history, peripheral artery disease and cancer were more common in the CC group, although the prevalence of COPD did not differ between the two groups. Prescription rate of loop diuretics was higher, as were B-type natriuretic peptide levels, while eGFR and sodium levels were lower in the CC group. Echocardiography revealed no significant differences between the two groups, except for higher tricuspid regurgitation pressure gradient in the CC group.

###### Patient characteristics.

                                    Non-CC (*n* = 1432)       CC (*n* = 176)      *P* value
  -------------------------------- ---------------------- ---------------------- -----------
  Demographic data                                                               
   Age, yrs                          68.0 (58.0--76.0)      76.0 (67.0--81.0)     \< 0.001
   Male sex                             892 (62.3%)             86 (48.9%)          0.001
   Body mass index, kg/m^2^          23.4 (21.5--26.0)      18.2 (17.2--19.1)     \< 0.001
   Systolic blood pressure, mmHg    123.0 (108.0--140.0)   117.5 (101.5--137.0)     0.021
  Past medical history                                                           
   Hypertension                         994 (69.4%)            107 (60.8%)          0.020
   Diabetes mellitus                    567 (39.6%)             70 (39.8%)          0.964
   Atrial fibrillation                  576 (40.2%)             69 (39.2%)          0.795
   Coronary artery disease              444 (31.0%)             45 (25.6%)          0.139
   Peripheral artery disease            152 (17.2%)             25 (28.4%)          0.009
   Cerebrovascular disease              257 (17.9%)             39 (22.2%)          0.174
   Cancer                               257 (18.7%)             43 (25.9%)          0.026
   COPD                                 357 (29.0%)             46 (32.4%)          0.397
  Medications at discharge                                                       
   β blockers                           1086 (75.8%)           125 (71.0%)          0.162
   ACEIs/ARBs                           1035 (72.3%)           116 (65.9%)          0.077
   Loop diuretics                       949 (66.3%)            138 (78.4%)          0.001
  Laboratory data                                                                
   C-reactive protein, mg/L            1.5 (0.6--6.0)        6.7 (1.0--19.4)      \< 0.001
   Hemoglobin, g/dL                  13.2 (11.6--14.6)       11.0 (9.9--11.9)     \< 0.001
   Albumin, g/dL                       3.9 (3.5--4.3)         3.4 (2.9--3.8)      \< 0.001
   BNP, pg/mL                       189.3 (67.0--495.1)    468.7 (202.7--827.9)   \< 0.001
   eGFR, mL/min per 1.73 m^2^        59.8 (46.3--73.2)      56.3 (35.8--74.0)       0.036
   Sodium, mEq/L                    140.0 (138.0--142.0)   138.0 (135.0--140.0)   \< 0.001
  Echocardiographic data                                                         
   LVEF, %                           53.6 (39.0--63.9)      56.2 (40.7--63.0)       0.513
   TR-PG, mmHg                       24.6 (19.0--35.0)      33.0 (21.6--40.3)     \< 0.001
   RV-FAC, %                         41.7 (31.9--48.5)      41.7 (34.1--47.9)       0.968

Data are presented as *n* (%) or median (interquartile range). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BNP: B-type natriuretic peptide; CC: cardiac cachexia; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; RV-FAC: right ventricular fractional area change; TR-PG: tricuspid regurgitation pressure gradient.

3.2. Post-discharge prognosis {#s3b}
-----------------------------

During the post-discharge follow-up period of median 1,295 days, there were 483 cardiac events and 419 all-cause deaths. The Kaplan-Meier analysis revealed that cardiac event rate and all-cause mortality were higher in the CC group than in the non-CC group ([Figure 1](#jgc-17-01-026-g001){ref-type="fig"}, log-rank *P* \< 0.001, respectively). In the univariable Cox proportional hazard analysis, CC was associated with both cardiac event \[hazard ratio (HR) = 2.609, 95% confidence interval (CI): 2.078--3.277, *P* \< 0.001\] and all-cause death (HR = 3.246, 95% CI: 2.587--4.071, *P* \< 0.001). Additionally, with respect to other risk factors, CC showed significant interactions with sex, cancer, loop diuretics, eGFR, and sodium in predicting cardiac event ([Table 2](#jgc-17-01-026-t02){ref-type="table"}). On the other hand, there were significant interactions between CC and age, hypertension, cancer, albumin, B-type natriuretic peptide, eGFR, and sodium in predicting all-cause death ([Table 3](#jgc-17-01-026-t03){ref-type="table"}).

![Kaplan-Meier analysis.\
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###### Interactions between presence of CC and other risk factors in predicting cardiac event (event *n* = 483/1608).

                               Subgroup       HR (95% CI)        *P* value   Interaction *P* value
  --------------------------- ---------- ---------------------- ----------- -----------------------
  Age                           Non-CC    1.030 (1.021--1.038)   \< 0.001            0.250
                                  CC      1.017 (1.002--1.033)     0.030    
  Male Sex                      Non-CC    0.962 (0.785--1.179)     0.709             0.020
                                  CC      1.588 (1.051--2.400)     0.028    
  Body mass index               Non-CC    0.981 (0.956--1.007)     0.142             0.547
                                  CC      1.023 (0.873--1.199)     0.776    
  Systolic blood pressure       Non-CC    0.995 (0.992--0.999)     0.020             0.202
                                  CC      1.000 (0.994--1.007)     0.948    
  Hypertension                  Non-CC    1.417 (1.117--1.798)     0.004             0.194
                                  CC      1.050 (0.686--1.607)     0.822    
  Diabetes mellitus             Non-CC    1.717 (1.408--2.094)   \< 0.001            0.592
                                  CC      1.472 (0.976--2.220)     0.065    
  Atrial fibrillation           Non-CC    1.614 (1.323--1.968)   \< 0.001            0.452
                                  CC      1.351 (0.895--2.040)     0.152    
  Coronary artery disease       Non-CC    1.116 (0.904--1.379)     0.306             0.107
                                  CC      1.618 (1.034--2.533)     0.035    
  Peripheral artery disease     Non-CC    1.593 (1.187--2.137)     0.002             0.256
                                  CC      1.046 (0.525--2.085)     0.898    
  Cerebrovascular disease       Non-CC    1.223 (0.955--1.565)     0.111             0.321
                                  CC      0.922 (0.561--1.514)     0.749    
  Cancer                        Non-CC    1.375 (1.074--1.761)     0.011             0.016
                                  CC      0.649 (0.376--1.119)     0.120    
  COPD                          Non-CC    1.514 (1.207--1.900)   \< 0.001            0.795
                                  CC      1.434 (0.888--2.317)     0.141    
  β-blockers                    Non-CC    1.642 (1.258--2.144)   \< 0.001            0.888
                                  CC      1.731 (1.043--2.875)     0.034    
  ACEIs/ARBs                    Non-CC    1.314 (1.030--1.677)     0.028             0.606
                                  CC      1.163 (0.745--1.816)     0.507    
  Loop diuretics                Non-CC    4.148 (3.066--5.610)   \< 0.001            0.035
                                  CC      2.047 (1.137--3.685)     0.017    
  C-reactive protein            Non-CC    0.999 (0.996--1.003)     0.694             0.590
                                  CC      0.997 (0.991--1.003)     0.386    
  Hemoglobin                    Non-CC    0.854 (0.817--0.893)   \< 0.001            0.846
                                  CC      0.870 (0.772--0.981)     0.023    
  Albumin                       Non-CC    0.612 (0.525--0.713)   \< 0.001            0.114
                                  CC      0.834 (0.598--1.164)     0.286    
  Log-BNP                       Non-CC    2.725 (2.249--3.302)   \< 0.001            0.282
                                  CC      1.891 (1.139--3.138)     0.014    
  eGFR                          Non-CC    0.974 (0.970--0.979)   \< 0.001            0.028
                                  CC      0.986 (0.978--0.994)     0.001    
  Sodium                        Non-CC    0.925 (0.901--0.949)   \< 0.001           \<0.001
                                  CC      1.017 (0.973--1.064)     0.454    
  LVEF                          Non-CC    0.985 (0.978--0.991)   \< 0.001            0.939
                                  CC      0.985 (0.970--1.000)     0.050    
  TR-PG                         Non-CC    1.001 (1.000--1.002)     0.006             0.474
                                  CC      0.996 (0.983--1.010)     0.584    
  RV-FAC                        Non-CC    0.992 (0.981--1.003)     0.134             0.314
                                  CC      1.004 (0.980--1.028)     0.761    

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CC: cardiac cachexia; COPD: chronic obstructive pulmonary disease; CI: confidence interval; eGFR: estimated glomerular filtration rate; HR: hazard ratio; Log-BNP: log-transformed B-type natriuretic peptide; LVEF: left ventricular ejection fraction; TR-PG: tricuspid regurgitation pressure gradient; RV-FAC: right ventricular fractional area change.

###### Interactions between presence of CC and other risk factors in predicting all-cause death (event *n* = 419/1,608).

                               Subgroup       HR (95% CI)        *P* value   Interaction *P* value
  --------------------------- ---------- ---------------------- ----------- -----------------------
  Age                           Non-CC    1.056 (1.045--1.067)   \< 0.001            0.003
                                  CC      1.022 (1.006--1.039)     0.009    
  Male Sex                      Non-CC    1.110 (0.884--1.393)     0.370             0.108
                                  CC      1.552 (1.042--2.313)     0.031    
  Body mass index               Non-CC    0.949 (0.920--0.978)     0.001             0.557
                                  CC      0.909 (0.785--1.053)     0.203    
  Systolic blood pressure       Non-CC    0.997 (0.993--1.001)     0.186             0.150
                                  CC      1.003 (0.997--1.009)     0.385    
  Hypertension                  Non-CC    1.345 (1.028--1.760)     0.031             0.009
                                  CC      0.734 (0.490--1.100)     0.134    
  Diabetes mellitus             Non-CC    1.409 (1.132--1.754)     0.002             0.066
                                  CC      0.925 (0.614--1.394)     0.710    
  Atrial fibrillation           Non-CC    1.451 (1.165--1.806)     0.001             0.077
                                  CC      0.954 (0.637--1.431)     0.821    
  Coronary artery disease       Non-CC    1.232 (0.980--1.548)     0.074             0.468
                                  CC      1.452 (0.940--2.245)     0.093    
  Peripheral artery disease     Non-CC    1.592 (1.142--2.218)     0.006             0.428
                                  CC      1.188 (0.616--2.294)     0.607    
  Cerebrovascular disease       Non-CC    1.460 (1.130--1.886)     0.004             0.187
                                  CC      1.025 (0.637--1.649)     0.919    
  Cancer                        Non-CC    2.594 (2.047--3.287)   \< 0.001            0.012
                                  CC      1.239 (0.772--1.990)     0.375    
  COPD                          Non-CC    1.229 (0.946--1.596)     0.123             0.757
                                  CC      1.130 (0.698--1.830)     0.618    
  β blockers                    Non-CC    1.002 (0.772--1.301)     0.988             0.872
                                  CC      0.952 (0.610--1.486)     0.830    
  ACEIs/ARBs                    Non-CC    0.800 (0.627--1.022)     0.074             0.667
                                  CC      0.719 (0.476--1.086)     0.117    
  Loop diuretics                Non-CC    2.103 (1.594--2.775)   \< 0.001            0.093
                                  CC      1.275 (0.764--2.127)     0.353    
  C-reactive protein            Non-CC    1.003 (1.000--1.005)     0.035             0.625
                                  CC      1.001 (0.996--1.006)     0.610    
  Hemoglobin                    Non-CC    0.768 (0.732--0.806)   \< 0.001            0.238
                                  CC      0.839 (0.743--0.947)     0.005    
  Albumin                       Non-CC    0.469 (0.398--0.553)   \< 0.001            0.022
                                  CC      0.718 (0.525--0.982)     0.038    
  Log-BNP                       Non-CC    3.184 (2.546--3.983)   \< 0.001            0.015
                                  CC      1.733 (1.067--2.814)     0.026    
  eGFR                          Non-CC    0.973 (0.968--0.979)   \< 0.001           \<0.001
                                  CC      0.991 (0.984--0.999)     0.029    
  Sodium                        Non-CC    0.913 (0.889--0.938)   \< 0.001           \<0.001
                                  CC      0.996 (0.956--1.037)     0.833    
  LVEF                          Non-CC    0.985 (0.977--0.992)   \< 0.001            0.987
                                  CC      0.986 (0.971--1.000)     0.055    
  TR-PG                         Non-CC    1.001 (1.001--1.002)     0.001             0.445
                                  CC      0.996 (0.983--1.010)     0.613    
  RV-FAC                        Non-CC    0.997 (0.984--1.009)     0.606             0.590
                                  CC      1.004 (0.981--1.027)     0.738    

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CC: cardiac cachexia; COPD: chronic obstructive pulmonary disease; CI: confidence interval; eGFR: estimated glomerular filtration rate; HR: hazard ratio; Log-BNP: log-transformed B-type natriuretic peptide; LVEF: left ventricular ejection fraction; TR-PG: tricuspid regurgitation pressure gradient; RV-FAC: right ventricular fractional area change.

Next, we focused on the CC group (*n* = 176) and performed a multivariable Cox proportional hazard analysis ([Table 4](#jgc-17-01-026-t04){ref-type="table"}). Factors which had *P* values of \< 0.05 in the univariable Cox analysis of a subgroup of CC in [Tables 2](#jgc-17-01-026-t02){ref-type="table"} and [3](#jgc-17-01-026-t03){ref-type="table"} were analyzed. With regard to predicting cardiac event, use of â blockers (HR = 1.900, 95% CI: 1.045--3.455, *P* = 0.035) and eGFR (HR = 0.989, 95% CI: 0.980--0.998, *P* = 0.018) were independent predictors. On the other hand, age (HR = 1.020, 95% CI: 1.002--1.039, *P* = 0.029) and hemoglobin (HR = 0.844, 95% CI: 0.734--0.970, *P* = 0.017) were independent predictors of all-cause death. The survival CART analysis revealed the optimal cut-off points in predicting both cardiac event (eGFR, 59.9 mL/min per 1.73 m^2^) and all-cause death (age, 83 years old; hemoglobin, 10.1 g/dL) in the CC group. Finally, these cut-off points were verified by Kaplan-Meier analysis. CC patients with eGFR of ≤ 59.9 mL/min per 1.73 m^2^ experienced more cardiac event ([Figure 2](#jgc-17-01-026-g002){ref-type="fig"}, log-rank *P* = 0.001). Similarly, CC patients with age \> 83 years old, and those with hemoglobin of ≤ 10.1 g/dL had a higher rate of all-cause death ([Figure 3](#jgc-17-01-026-g003){ref-type="fig"}, log-rank *P* \< 0.001 and *P* = 0.004, respectively).

###### Cox proportional hazard analysis in the CC group (*n* = 176).

                                              Univariable        Multivariable                         
  -------------------------------------- ---------------------- --------------- ---------------------- -------
  Cardiac event (event *n* = 92/176)                                                                   
   Age                                    1.017 (1.002--1.033)       0.030       1.013 (0.995--1.031)   0.171
   Male sex                               1.588 (1.051--2.400)       0.028       1.265 (0.801--1.999)   0.314
   CAD                                    1.618 (1.034--2.533)       0.035       1.332 (0.823--2.157)   0.244
   β-blockers                             1.731 (1.043--2.875)       0.034       1.900 (1.045--3.455)   0.035
   Loop diuretics                         2.047 (1.137--3.685)       0.017       1.769 (0.909--3.443)   0.093
   Hemoglobin                             0.870 (0.772--0.981)       0.023       0.897 (0.789--1.018)   0.093
   Log-BNP                                1.891 (1.139--3.138)       0.014       1.411 (0.825--2.413)   0.209
   eGFR                                   0.986 (0.978--0.994)       0.001       0.989 (0.980--0.998)   0.018
  All-cause death (event *n* = 98/176)                                                                 
   Age                                    1.022 (1.006--1.039)       0.009       1.020 (1.002--1.039)   0.029
   Male sex                               1.552 (1.042--2.313)       0.031       1.313 (0.849--2.032)   0.221
   Hemoglobin                             0.839 (0.743--0.947)       0.005       0.844 (0.734--0.970)   0.017
   Albumin                                0.718 (0.525--0.982)       0.038       0.860 (0.576--1.284)   0.461
   Log-BNP                                1.733 (1.067--2.814)       0.026       1.611 (0.955--2.716)   0.074
   eGFR                                   0.991 (0.984--0.999)       0.029       0.995 (0.987--1.004)   0.264

CAD: coronary artery disease; CC: cardiac cachexia; CI: confidence interval; eGFR: estimated glomerular filtration rate; HR: hazard ratio; Log-BNP: log-transformed B-type natriuretic peptide.

![Kaplan-Meier analysis for cardiac event in the CC group.\
CC: cardiac cachexia; eGFR: estimated glomerular filtration rate.](jgc-17-01-026-g002){#jgc-17-01-026-g002}

![Kaplan-Meier analysis for all-cause death in the CC group.\
CC: cardiac cachexia.](jgc-17-01-026-g003){#jgc-17-01-026-g003}

4. Discussion {#s4}
=============

To the best of our knowledge, the present study is the first to focus on the interactions between CC and other important risk factors, as well as the first to determine independent prognostic factors in HF patients with CC. The main findings of this study were that (1) the presence of CC showed significant interactions with several important risk factors in predicting post-discharge prognosis, and (2) eGFR, age, and hemoglobin were independent predictors of post-discharge prognosis in patients with CC accompanied by useful cut-off points determined by the survival CART analysis.

The term "cachexia" comes from the Greek words kakós (bad) and hexis (condition or appearance), and is described as wasting.[@b2],[@b9] The CC group in this study demonstrated several unfavorable features as suggested by the name cachexia. Lower BMI in patients with HF suggests systemic inflammation, catabolism and higher right heart pressure, and is associated with higher cardiac and all-cause mortality.[@b18] Peripheral artery disease also predicts higher mortality and deteriorates exercise capacity because of its arterial obstruction, endothelial dysfunction, mitochondrial dysfunction, and inflammatory activation.[@b17],[@b21] Regarding other cachexia-associated comorbidities, the prevalence of COPD was similar between the CC and non-CC groups. However, COPD in patients with HF can be underrecognized, because both conditions exhibit similar symptoms (e.g., dyspnea and fatigue).[@b19],[@b20] COPD can lead to cachexia and is a predictor of adverse prognosis in patients with HF.[@b20],[@b22],[@b23] In the current study, the prevalence of cancer was higher and eGFR was lower in the CC group. These results suggest that cancer cachexia, CKD cachexia, and CC can coexist, or that one type of cachexia can lead to other types of cachexia. Patients with cancer cachexia experience cardiac atrophy and HF through underlying heart disease, cancer itself, or cardiotoxic effects of cancer treatment.[@b24]--[@b26] Kottgen, *et al*.[@b27] collected the data of a community-based prospective cohort and found that patients with eGFR of \< 60 mL/min per 1.73 m^2^ had a 1.94-fold risk of incident HF compared to those with normal eGFR. Like this condition in which CKD contributes to HF, CKD cachexia causes HF.[@b14] Hasin, *et al*.[@b28] reported in their case-control study that patients with HF had a 1.68-fold risk of developing new cancer. In addition, the authors of the present study recently reported that HF patients with preexisting cancer demonstrated higher prevalence of CKD, COPD, and anemia compared to those without preexisting cancer.[@b15] These cachexia-associated vicious cross-talk have been explained by shared pathophysiology: metabolic disturbance, oxidative stress, chronic inflammation, and neurohormonal activation.[@b2],[@b14],[@b15],[@b25],[@b29] Thus, effective cachexia treatment requires the collaboration of various physicians, including cardiologists, oncologists, nephrologists, and pulmonologists.

With respect to prognosis prediction, we found several significant interactions between CC and other important factors. If the interactions were significant, the HRs of the CC group were all attenuated compared to those in the non-CC group except for male sex in predicting cardiac event. Cancer and sodium showed significant interactions with CC in predicting both cardiac event and all-cause death, suggesting that they were no longer associated with these endpoints in the CC group. Since cachexia is a condition that occurs following cancer and activation of renin-angiotensin-aldosterone system,[@b2],[@b5] the prognostic impacts of these factors would decrease when cachexia develops. However, these explanations remain a matter of speculation. Considering the results shown in [Tables 2](#jgc-17-01-026-t02){ref-type="table"} and [3](#jgc-17-01-026-t03){ref-type="table"}, physicians should keep in mind that the prognostic impact of general risk factors can be altered on the basis of the presence or absence of CC in patients with HF.

In our patients with CC, the cut-off value of eGFR in predicting cardiac event was similar to the cut-off value of CKD of 60 mL/min per 1.73 m^2^, which seemed to be reasonable and acceptable.[@b30] The cut-off value of hemoglobin for predicting all-cause death was slightly lower than the cut-off value for CC diagnosis. Although the causes of decreased hemoglobin (e.g., deficiency of iron, vitamin B12 or folic acid, renal anemia, or occult bleeding) were unclear, anemic patients with CC were presumed to be associated with advanced myocardial remodeling, inflammation, and volume overload.[@b31] The results from the multivariable Cox proportional hazard analysis of the current study suggest that eGFR and hemoglobin are pivotal biomarkers in patients with CC.

The limitations of this study are worth noting to avoid overstating the results. For the first, the diagnostic criteria of CC included BMI at discharge, not weight loss within a certain period. Secondly, since this was a single-center study with a relatively small number of patients, our results should be considered as preliminary. Further studies including large population and consideration of pre- and post-discharge weight change are required.
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